When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Hospital and ambulatory care operator Tenet Healthcare Co. NYSE: THC is operating in the sweet spot of healthcare these days. That sweet spot is acute care services, which include emergency departments, inpatient hospitalizations, and ambulatory care.
Hospital operator Tenet Healthcare said on Monday that it will sell five hospitals with Brookwood Baptist Health in Birmingham to Orlando Health for about $910 million in cash.
Tenet (THC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tenet (THC) shares jump 8.3% since Q2 earnings beat, as investors grow increasingly confident about the company's future prospects.
Does Tenet Healthcare (THC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tenet (THC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Tenet Healthcare (THC) shares soared to a more than two-decade high after the hospital and surgical center chain posted stronger-than-expected results and boosted its outlook as it brought in more patients who paid more for services.
Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.